The 3 most recent market catalysts affecting $RLMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 55
Relmada Therapeutics Appoints Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology
Relmada Therapeutics has appointed Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology. This is a positive development for the company as Dr. Jakobsen bring…
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 80
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics reported its Q3 2026 financial results and provided a business update. The key takeaways are the positive 18-month Phase 2 results for NDV-01, showing extended…
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 65
Relmada Therapeutics shares are trading higher after Form 4 filings showed its executives bought company stock.
The Form 4 filings indicating executive stock purchases are a strong positive signal for Relmada Therapeutics. Insider buying suggests that those with the most intimate knowledge o…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.